The cobas EZH2 Test was developed by Roche Molecular Systems, Inc. (Branchburg, New Jersey), as part of a precision medicine strategy adopted in the design of a drug study conducted by Epizyme, Inc., to assess the efficacy of tazemetostat treatment in FL and DLBCL patients, including those with mutations in the EZH2 gene (MD, positive) as well as in those with WT status (NMD, negative) determined by the cobas EZH2 Test. This evidence concerns the gene EZH2 and diffuse large B-cell lymphoma.